ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SYSTEM SCLEROSIS PULMONARY AVEOLITIS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究旨在评估环磷酰胺（一种强抗炎和免疫抑制药物，商号为环磷酰胺）在预防硬皮病肺损伤恶化方面是否优于安慰剂（一种惰性的、无效的治疗方法）。这条轨道将比较每天每公斤2毫克环磷酰胺（片剂约100-150毫克）和安慰剂，后者看起来像环磷酰胺，但是惰性的，考虑到剂量调整的毒性。在几个中心先前的研究中，肺功能的改善在开始使用环磷酰胺后发生。在最近的一项研究中，3/4的环磷酰胺患者和1/4未接受治疗的患者的肺功能改善超过10%。本研究旨在以科学的方式检验环磷酰胺是否真的能改善早期肺部受累的硬皮病患者的肺功能。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has been designed to evaluate whether cyclophosphamide (a strong anti-inflammatory and immunosuppressant medication, trade named Cytoxan) is better than placebo (an inert, no effective treatment) in preventing lung damage from scleroderma from getting worse. This rail will compare 2 milligrams per kilogram per day of cyclophosphamide (approximately 100-150 mg in tablet form) with a placebo that looks like cyclophosphamide but is inert, with allowances for dose adjustments for toxicity. In previous studies from several centers, improvement in lung function was reported to have occurred after starting cyclophosphamide. In one recent study, lung function improved by greater than 10% in 3/4 of the cyclophosphamide patients and in 1/4 of the non-treated patients. This study is designed toexamine in a scientific fashion whether cyclophosphamide does actually improve lung function in people with scleroderma with early lung involvement.